A trio of former Palantir executives who helped spearhead that company’s Life Sciences practice have founded a startup called Perceptic that is building an end-to-end AI platform for drug development, handling everything from drug discovery to clinical trial design. The company emerged from stealth today and announced a $12 million seed funding round. London-based venture capital firm Accel led the funding round, alongside Air Street Capital and Elder Gull. The company’s valuation following the ...